Glenview Trust Co Acquires 37,641 Shares of Stryker Corporation $SYK

Glenview Trust Co grew its stake in shares of Stryker Corporation (NYSE:SYK) by 839.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 42,125 shares of the medical technology company’s stock after acquiring an additional 37,641 shares during the quarter. Glenview Trust Co’s holdings in Stryker were worth $11,601,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of SYK. Amundi raised its holdings in shares of Stryker by 18.3% in the 2nd quarter. Amundi now owns 1,246,353 shares of the medical technology company’s stock worth $392,402,000 after purchasing an additional 192,447 shares during the period. The Manufacturers Life Insurance Company grew its holdings in shares of Stryker by 8.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 859,544 shares of the medical technology company’s stock worth $270,642,000 after purchasing an additional 65,333 shares during the period. Veritas Asset Management LLP purchased a new stake in shares of Stryker during the 2nd quarter worth about $168,057,000. Bank of America Corp DE acquired a new stake in Stryker during the 2nd quarter worth approximately $1,404,284,000. Finally, Rakuten Investment Management Inc. acquired a new stake in Stryker during the 2nd quarter worth approximately $18,646,000. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Stryker news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the completion of the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This represents a 6.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares of the company’s stock, valued at $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock worth $118,197,701 over the last 90 days. Company insiders own 4.60% of the company’s stock.

Stryker Price Performance

SYK stock opened at $291.56 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. Stryker Corporation has a 1 year low of $267.00 and a 1 year high of $389.33. The firm has a market cap of $111.83 billion, a P/E ratio of 31.05, a price-to-earnings-growth ratio of 2.01 and a beta of 0.78. The stock has a 50-day simple moving average of $292.83 and a 200-day simple moving average of $324.51.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing the consensus estimate of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a return on equity of 23.83% and a net margin of 13.78%. The business’s revenue was up 7.6% on a year-over-year basis. During the same period last year, the firm posted $3.19 earnings per share. On average, equities analysts predict that Stryker Corporation will post 14.93 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were paid a dividend of $0.88 per share. The ex-dividend date was Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.2%. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Analyst Upgrades and Downgrades

SYK has been the topic of several research reports. Stifel Nicolaus cut their price target on shares of Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. Royal Bank Of Canada decreased their price objective on shares of Stryker from $420.00 to $375.00 and set an “outperform” rating for the company in a research note on Friday. BTIG Research dropped their price objective on shares of Stryker from $316.00 to $304.00 and set a “buy” rating for the company in a research report on Friday. Citizens Jmp cut their target price on shares of Stryker from $400.00 to $390.00 and set a “market outperform” rating on the stock in a research note on Friday. Finally, Wall Street Zen downgraded shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Sixteen equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and a consensus target price of $355.84.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Quarterly revenue increased 7.6% year over year to $6.52 billion, while adjusted earnings rose to $3.52 per share from $3.19 a year earlier. Management also cited strength in MedSurg, margin improvement and continued investment in robotic surgery. Stryker reports third quarter 2026 operating results
• Positive Sentiment: Despite lower forecasts, several analysts remain constructive. Barclays maintained an overweight rating with a $365 target, while Citizens JMP kept “market outperform” at $390 and RBC retained “outperform” with a $375 target. RBC cuts price target on Stryker
• Neutral Sentiment: Analyst sentiment has become more divided. Citigroup cut its target to $315 but kept a buy rating, BTIG reduced its target to $304 while maintaining buy, and TD Cowen lowered its target to $290 with a hold rating. Canaccord also downgraded the shares to hold and cut its target to $300.
• Negative Sentiment: Third-quarter adjusted EPS of $3.52 and revenue of $6.52 billion missed consensus estimates of $3.55 and $6.62 billion, respectively. Stryker Q3 earnings and revenues lag estimates
• Negative Sentiment: Stryker cut its 2026 forecast to 6.5%-7.0% organic sales growth and $14.80-$14.90 adjusted EPS, from previous ranges of 8.3%-9.3% and $14.95-$15.10. Weaker joint-replacement demand, supply disruptions and ongoing peripheral-vascular manufacturing problems are weighing on expectations. SYK stock outlook cut

Stryker Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.